APA (7th ed.) Citation

Krug, L. M., & Manegold, C. (2015). Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial. The lancet. Oncology, 16(4), . https://doi.org/10.1016/S1470-2045(15)70056-2

Chicago Style (17th ed.) Citation

Krug, Lee M., and Christian Manegold. "Vorinostat in Patients with Advanced Malignant Pleural Mesothelioma Who Have Progressed on Previous Chemotherapy (VANTAGE-014): A Phase 3, Double-blind, Randomised, Placebo-controlled Trial." The Lancet. Oncology 16, no. 4 (2015). https://doi.org/10.1016/S1470-2045(15)70056-2.

MLA (9th ed.) Citation

Krug, Lee M., and Christian Manegold. "Vorinostat in Patients with Advanced Malignant Pleural Mesothelioma Who Have Progressed on Previous Chemotherapy (VANTAGE-014): A Phase 3, Double-blind, Randomised, Placebo-controlled Trial." The Lancet. Oncology, vol. 16, no. 4, 2015, https://doi.org/10.1016/S1470-2045(15)70056-2.